These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
590 related articles for article (PubMed ID: 28190113)
1. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure. Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113 [TBL] [Abstract][Full Text] [Related]
2. Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study. Iwatani H; Kawabata H; Sakaguchi Y; Yamamoto R; Hamano T; Rakugi H; Isaka Y Nephron; 2015; 130(1):8-12. PubMed ID: 25926290 [TBL] [Abstract][Full Text] [Related]
3. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study. Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y Am J Nephrol; 2017; 46(5):417-426. PubMed ID: 29130954 [TBL] [Abstract][Full Text] [Related]
4. The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure. Otsuka T; Sakai Y; Ohno D; Murasawa T; Sato N; Tsuruoka S Clin Exp Nephrol; 2013 Dec; 17(6):834-8. PubMed ID: 23483323 [TBL] [Abstract][Full Text] [Related]
5. Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study. Minami S; Hamano T; Iwatani H; Mizui M; Kimura Y; Isaka Y Clin Exp Nephrol; 2018 Jun; 22(3):550-561. PubMed ID: 29052786 [TBL] [Abstract][Full Text] [Related]
6. Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin. Kadota M; Ise T; Yagi S; Iwase T; Akaike M; Ueno R; Kawabata Y; Hara T; Ogasawara K; Bando M; Bando S; Matsuura T; Yamaguchi K; Yamada H; Soeki T; Wakatsuki T; Sata M Int Heart J; 2016 Jul; 57(4):461-5. PubMed ID: 27357439 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study. Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y Clin Exp Nephrol; 2018 Dec; 22(6):1395-1403. PubMed ID: 29934667 [TBL] [Abstract][Full Text] [Related]
8. Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure. Ikeda S; Ohshima K; Miyazaki S; Kadota H; Shimizu H; Ogimoto A; Hamada M ESC Heart Fail; 2017 Nov; 4(4):614-622. PubMed ID: 29154417 [TBL] [Abstract][Full Text] [Related]
9. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. Komiyama Y; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Yasui Y; Tamaki N; Takada H; Higuchi M; Gotou T; Kubota Y; Takaura K; Hayashi T; Oh W; Okada M; Enomoto N; Izumi N PLoS One; 2017; 12(3):e0174649. PubMed ID: 28362879 [TBL] [Abstract][Full Text] [Related]
10. [The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia]. Li L; Bai H; Zhu WL; Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):936-40. PubMed ID: 22321279 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tolvaptan for pediatric patients with congestive heart failure. Multicenter survey in the working group of the Japanese Society of PEdiatric Circulation and Hemodynamics (J-SPECH). Higashi K; Murakami T; Ishikawa Y; Itoi T; Ohuchi H; Kodama Y; Honda T; Masutani S; Yamazawa H; Senzaki H; Ishikawa S Int J Cardiol; 2016 Feb; 205():37-42. PubMed ID: 26710331 [TBL] [Abstract][Full Text] [Related]
12. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953 [TBL] [Abstract][Full Text] [Related]
13. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease. Imamura T; Kinugawa K; Shiga T; Kato N; Muraoka H; Minatsuki S; Inaba T; Maki H; Hatano M; Yao A; Kyo S; Nagai R Circ J; 2013; 77(2):397-404. PubMed ID: 23131721 [TBL] [Abstract][Full Text] [Related]
14. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C; Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial. Komiya S; Katsumata M; Ozawa M; Haze T; Kawano R; Ohki Y; Suzuki S; Kobayashi Y; Fujiwara A; Saka S; Tamura K; Hirawa N Clin Exp Nephrol; 2022 Sep; 26(9):851-858. PubMed ID: 35471469 [TBL] [Abstract][Full Text] [Related]
16. Impact of urine cyclic AMP relative to plasma arginine vasopressin on response to tolvaptan in patients with chronic kidney disease and heart failure. Kakeshita K; Koike T; Imamura T; Fujioka H; Yamazaki H; Kinugawa K Clin Exp Nephrol; 2023 May; 27(5):427-434. PubMed ID: 36752971 [TBL] [Abstract][Full Text] [Related]
17. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials. Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084 [TBL] [Abstract][Full Text] [Related]
18. Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey. Sağ S; Aydın Kaderli A; Yıldız A; Gül BC; Özdemir B; Baran İ; Güllülü S; Aydınlar A; Çavuşoğlu Y Turk Kardiyol Dern Ars; 2017 Jul; 45(5):415-425. PubMed ID: 28694395 [TBL] [Abstract][Full Text] [Related]
19. Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis. Mori T; Oba I; Koizumi K; Kodama M; Shimanuki M; Tanno M; Chida M; Saito M; Kiyomoto H; Miyazaki M; Ogawa S; Sato H; Ito S Adv Perit Dial; 2013; 29():33-7. PubMed ID: 24344488 [TBL] [Abstract][Full Text] [Related]
20. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study. Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]